PANDEMIC REPORT: Airway Therapeutics’ drug treatment | Don’t skip your second dose | Protease inhibitors

Drug treatment for the sickest COVID patients

CINCINNATI—Earlier this year, we reported that the FDA accepted Airway Therapeutics’ application for an investigational drug treatment designed to help some of the sickest coronavirus patients recover. The first patient has been dosed in a Phase 1b trial of AT-100 in severe COVID-19 patients and seems to be on the mend.

COVID and protease inhibitors

MANHATTAN, KS—Kansas State University has received a five-year, $3.7 million grant from the National Institutes of Health’s National Institute of Allergy and Infectious Diseases to research a new treatment for the COVID-19 virus. The treatment method focuses on protease inhibitors.

Improving the logistics space

GRAND RAPIDS, MI—The pandemic has affected customer needs in the e-commerce and logistics spaces, with expectations for product delivery times becoming shorter. Dematic Corp., a supplier of material handling systems, software and solutions, has a $3 billion tech center, where it is shifting more of its focus to increasingly complex forms of conveyance solutions.

Don’t skip the second vaccine dose

A new study from Northwestern University examines why skipping the second vaccine dose is not a good idea. The study showed that two months after the second shot of a Pfizer or Moderna mRNA COVID-19 vaccine, the antibody response decreases by 20 percent in adults who have had COVID-19 previously.